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ABSTRACT
Background: Myocardial reperfusion is the main target of treatment in patients with ST-segment 
elevation myocardial infarction (STEMI). The intracoronary administration of cangrelor bolus could 
favor a higher local drug concentration, favoring an earlier thrombotic resolution and a reduced distal 
micro-embolization.
Methods: Seventy-one patients undergoing primary percutaneous coronary intervention (PCI) for 
STEMI: 37 treated with intracoronary and 34 with intravenous bolus administration of cangrelor. The 
primary endpoint was ST-elevation reduction (STR) ≥ 50% after 30 min from the end of the PCI. 
Other explorative reperfusion indices investigated were: STR ≥ 50% at 24 hours, STR ≥ 70% at 30 
min, Thrombolysis In Myocardial Infarction frame count and the QT dispersion (QTd). Moreover, 
acute and subacute stent thrombosis, bleeding events and 30-day mortality have been evaluated.
Results: More frequent STR ≥ 50% was observed in the intravenous cangrelor bolus group as 
compared to the intracoronary administration at 30 min (71.9% vs. 45.5%; p = 0.033), the difference 
was maintained 24 hours after PCI (87.1% vs. 63.6%; p = 0.030). STR ≥ 70% at 30 min was 
statistically more frequent in the intravenous bolus administration cohort (66.7% vs. 28.6% p = 0.02). 
At multivariable analysis, intravenous cangrelor administration was significantly related to STR ≥ 
50% (odds ratio: 3.586; 95% confidence interval: 1.134–11.335; p = 0.030). The incidence of 
Bleeding Academic Research Consortium 3–5 bleedings was 15.5% and mortality was 4.2% without 
any significant difference between the two groups.
Conclusions: In conclusion the results of the study do not show any advantages in the administration 
of intracoronary bolus of cangrelor in patients affected by STEMI and treated with primary PCI.
Key words: primary percutaneous coronary intervention, ST-segment elevation myocardial 
infarction, cangrelor, intracoronary bolus administration, ST elevation resolution, myocardial 
reperfusion
INTRODUCTION
Myocardial reperfusion is the main target of the treatment strategy in patients with 
ST-segment elevation myocardial infarction (STEMI). The most powerful oral P2Y12-receptor
inhibitors, prasugrel and ticagrelor, showed a several hour time-frame delay in their activity 
onset, especially in patients presenting with STEMI [1]. Thus, in this setting it is crucial to 
have an intravenous drug available with a faster and intense platelet inhibition. The use of 
antithrombotic glycoprotein IIb/IIIa receptor inhibitors (GPI) is associated with a high 
bleeding risk, and currently their use should be considered for bailout situations (evidence of
no-reflow or thrombotic complications) or angiographic evidence of massive intracoronary 
thrombosis during percutaneous coronary intervention (PCI).
Cangrelor is an intravenous P2Y12 receptor antagonist and it reaches its therapeutic 
concentration within minutes. It is indicated in patients undergoing PCI, to reduce ischemic 
adverse events, in patients who have not received oral P2Y12 inhibitors before PCI or where
oral P2Y12 inhibition is not feasible or desirable. Cangrelor binds the P2Y12 receptor 
directly, so it does not need hepatic activation [2]; half-life is short, about 3–5 min, and it is
rapidly inactivated by hematic dephosphorilation [3–5]. It reversibly inhibits the P2Y12 
receptor after an initial bolus dose of 30 µg/kg followed by continuous infusion of 4 
µg/kg/min. The infusion is indicated for at least 2 hours or until the end of the procedure, 
whichever is longer. Platelet aggregation inhibition is achieved within a few minutes, and its 
restoration is achieved within 60–90 min after stopping the administration [2]. Thus, 
cangrelor is ideal in STEMI patients treated with primary PCI, because there is little time for 
pre-treatment with oral P2Y12 inhibitors and increased thrombotic risk. The safety and 
efficacy of cangrelor was investigated in 3pivotal  randomized clinical trials of the 
CHAMPION trial program (Cangrelor versus Standard Therapy to Achieve Optimal 
Management of Platelet Inhibition) and in the pooled analysis [6–8]. Patients with STEMI 
were only about 12% of the study population in CHAMPION, but with a consistent 19% 
relative reduction of the composite primary end point. More recently, the pharmacodynamic 
evidence effects of cangrelor in combination with ticagrelor for patients treated with primary 
PCI was investigated in the CANTIC study (Platelet Inhibition with Cangrelor and Crushed
Ticagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention) [9].
Intracoronary administration of abciximab or other GPI during PCI constitutes a safe 
approach for drug administration and was associated with a significant improvement in 
myocardial perfusion despite no clear clinical benefit [10, 11]. Similarly, the intracoronary 
administration of cangrelor could favor a higher local drug concentration, leading to a deeper 
platelet inhibition in the clinical setting of primary PCI. This could be associated with an 
earlier thrombotic resolution and a reduced distal micro-embolization translating in 
myocardial reperfusion improvement. However, no data exists about the intracoronary 
administration of cangrelor in the management setting of primary PCIs.
The aim of this prospective study was to compare myocardial reperfusion assessed by 
ST-segment elevation resolution (STR) provided by intracoronary bolus or intravenous 
administration of cangrelor.
METHODS
Cangrelor became available in our institution from the beginning of 2019. In a 
prospective and nonrandomized fashion; thus, the study is exploratory and should be 
considered mainly as hypothesis generating, all consecutive patients enrolled were admitted 
for STEMI within 12 hours from symptoms onset treated with primary PCI, without any 
restriction based on age or clinical status at presentation. Patients with a history of oral 
P2Y12 inhibitor therapy or treated with clopidogrel, prasugrel or ticagrelor before the 
procedure or with anticoagulant were excluded. Other exclusion criteria were: 
administration of intravenous thrombolysis or use of an extracorporeal life support device; 
major surgery < 6 weeks; stroke < 30 days or any history of hemorrhagic stroke; 
participation in another study and patients presenting pacemaker rhythm or with left bundle 
block.
According to institutional protocol, after the confirmed diagnosis of STEMI, patients 
received intracoronary or intravenous cangrelor bolus after diagnostic coronary angiography, 
at operator’s discretion.
Selective coronary angiography was performed in multiple projections before 
mechanical reperfusion. The preferred access was radial. Immediately after diagnostic 
angiography, antithrombotic and anticoagulant treatment was administered and primary PCI
intervention with drug eluting stenting of the infarct-related vessel was performed using 
standard material. Mechanical thrombectomy was performed at the operators’ discretion in 
case of massive intracoronary thrombosis and in case of thrombotic complications. Successful 
primary PCI was defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3 coronary 
flow in the treated vessel with a residual stenosis < 20%. Acetylsalicylic acid was 
administered to all patients before primary PCI (150 to 300 mg orally or 150 mg 
intravenously). During the procedure, intravenous unfractioned heparin was administered 
accordingly to achieve an activated clotting time of 250–300 s. Cangrelor bolus dose was 
administered as recommended according to patient weight (30 µg/kg bolus followed by 4 
µg/kg/min continuous infusion for 2 h) after the diagnostic angiography by central/peripheral 
vein or intracoronary through the guiding catheter after the cannulation of culprit infarct-
related artery. After the procedure, cangrelor infusion was continued by central/peripheral 
vein in all patients to reach the two recommended hours of treatment. At the end of the 
procedure, all patients received a loading dose of ticagrelor (180 mg) followed by 90 mg twice 
a day.
Primary end point of the study was a surrogate of myocardial reperfusion: the early 
STR ≥ 50% at 30 min after primary PCI. Other explorative surrogates of myocardial 
reperfusion included: a) the STR ≥ 70% at 30 min after PCI; b) the STR ≥ 50% at 24 hours 
after PCI; c) QT dispersion (QTd); d) post-procedural corrected TIMI frame count.
Electrocardiogram (ECG) was recorded 30-min and 24 hours after the procedure, using the
same electrocardiograph. The ST-segment changes were evaluated in the single lead with 
the most prominent ST-segment elevation before mechanical intervention. The ST-segment 
elevation was measured to the nearest 0.5 mm at 60 ms after the J point with the aid of a 
hand-held caliper. The STR was defined as a reduction in ST-segment elevation ≥ 50% or ≥ 
70% at 30 min and at 24 hours after primary PCI. To obtain the QTd measure, the QT interval 
length of every lead where it was easily readable (using the diagonal method) was measured, 
then every QT interval length was corrected (QTc) using the Bazett formula; finally, the 
difference between longest QTc and shortest one was calculated. TIMI frame count was 
measured considering the time in frames taken by the contrast to pass from the proximal to 
the distal part of the culprit vessel; the frame speed was 15 frames/s. We considered first 
frame to  be  when the contrast touched both the vessel walls and matted at least 70% of the
lumen. The distal markers position depended on the coronary: in the right coronary artery it
was the first collateral branch of the Posterior-lateral vessel; in the left anterior descending 
coronary artery (LAD) was the “whale tale”; in the circumflex coronary artery was at the more
distal part of the branches for the obtuse margin. The obtained frames have been doubled to 
correct the acquisition time from 15 frames/s to 30 frames/s, according to available literature. 
For the LAD, the total number of frames was divided by 1.7 (correction factor). 
All electrocardiographics and angiographic markers of reperfusion analyses were 
performed by physicians blinded to the cangrelor bolus administration route.
Adverse clinical outcomes within 30 days were collected including all-cause mortality, 
cardiovascular mortality, myocardial reinfarction, stroke, acute and sub-acute stent thrombosis 
according to the Academic Research Consortium [12, 13], urgent target vessel 
revascularization, unplanned revascularization, bleeding events according to Bleeding 
Academic Research Consortium (BARC) classification [14], and if clinically relevant (the 
need for blood transfusion or a reduction of hemoglobin more than 3 g/dL).
The study complied with the Declaration of Helsinki and Good Clinical Practice, and was 
approved by the institutional ethics committee, and patients or legal representatives signed 
written informed consent.
Patients were divided in two groups according to the cangrelor bolus administration 
(intravenous or intracoronary). Discrete data are expressed as frequencies, and continuous 
data as mean ± standard deviation or median and interquartile range, as appropriate. The χ test
was used to compare categorical variables, and the unpaired two-tailed Student t-test or 
Mann-Whitney rank-sum test was used to test differences between continuous variables. 
The univariable and multivariable analyses to evaluate the independent contribution of the 
variables to the primary and other explorative surrogate of myocardial reperfusion end 
points were performed by the binary logistic regression model. The variables that reached 
the highest significance at the univariable analysis were considered in the final 
multivariable model in order to avoid overfitting. The following variables were considered: 
mean age, female, LAD as the  culprit lesion, chronic kidney disease, diabetes, 
intraprocedural thrombectomy and intracoronary or intravenous cangrelor bolus 
administration. In order to minimize bias due to the nonrandomized nature of the study and 
the possibility of overfitting, a propensity score analysis was performed using a logistic 
regression model from which the probability for the intracoronary or intravenous bolus 
cangrelor administration was calculated for each patient; variables introduced into 
propensity score model were: age (years), female, diabetes, previous coronary 
revascularization, pre-procedural ST-segment elevation, and LAD coronary artery as the 
culprit vessel. Model discrimination was assessed with the C-statistic and goodness-of-fit 
with Hosmerand–Lemeshow test. Thereafter, a multivariable analysis was performed using the 
propensity score as a continuous covariate. Binary logistic multivariate analysis was used to 
test interaction between thrombectomy and intravenous or intracoronary cangrelor bolus 
administration. To compare the measures of the QTd and the TIMI frame count between the 
groups, the values above the median and above the 75° percentile were analyzed. All tests 
were two-tailed. A p value < 0.05 was considered significant. Analyses were performed with 
SPSS statistical package, Version 21 (IBM Corp., Armonk, NY, USA).
RESULTS
Out of 220 STEMI patients from March 2019 to August 2020, 77 were treated with 
Cangrelor and 71 were available for the analysis: 34 patients in the intravenous bolus 
administration group, and 37 patients in the intracoronary group (excluded patients: 4 had 
ventricular pace-maker complex, 2 had previous left bundle branch block).
Among the 71 patients who underwent cangrelor administration during primary PCI, 
baseline characteristics were well balanced between the two groups (Table 1). Mean age was 
65 ± 13, there were 21% of female patients. Diabetic patients accounted for the 17% of the 
study population and 15.5% of the patients had previous coronary revascularization. 
Angiographic and procedural characteristics are depicted in Table 2. At baseline ECG, 
there was no difference between the median values of ST-segment elevation in the 
intracoronary and intravenous groups (2.80 ± 1.61 mm vs. 2.78 ± 2.07 mm; p = 0.273). 
Radial access was used in 67.6% of patients; LAD was the culprit vessel in 40 (56.3%) 
cases. Intra-procedural rheolytic thrombectomy use differed between the two groups: 50% of
cases in intravenous bolus group vs. 13.4% in intracoronary bolus group (p = 0.002). 
Primary PCI was successful in all patients of the study cohort (post procedural TIMI 3 with 
a residual stenosis < 20%). All patients received second generation drug eluting stents (Table 
2). In all patients (100%) oral P2Y12 inhibitor was ticagrelor.
The early STR ≥ 50% primary end point was significantly higher in intravenous than 
intracoronary group (71.9% vs. 45.5%; p = 0.033) (Fig. 1). At univariable analysis, LAD 
as culprit vessel showed an inverse correlation with early ST-segment elevation resolution 
(odds ratio [OR] 0.283; 95% confidence interval [CI] 0.097–0.828; p=0.021) as well as 
chronic kidney disease (OR 0.159; 95% CI 0.030–0.838; p = 0.030). At multivariable 
analysis, intravenous cangrelor bolus administration was significantly related to STR ≥ 50% 
(OR 3.586; 95% CI  1.134–11.335; p = 0.030) and remained significantly associated with the
primary end point also after propensity score adjustment (OR 3.23; p = 0.032; C-statistic = 
0.67; p = 0.977 for Hosmer–Lemeshow test) (Table 3, Fig. 2).
STR ≥ 50% was evaluated also at 24 hours after the procedure as another explorative 
surrogate index of myocardial reperfusion, and intravenous bolus administration of 
cangrelor resulted i n  the only variable associated with STR in the multivariable analysis (OR
4.250; 95% CI 1.128–16.016; p = 0.033) (Table 3). Similar results were obtained with 30 min 
STR ≥ 70% (OR 5.591; 95% CI 1.859–16.819; p = 0.002) (Table 3). No interaction was 
found between thrombectomy and intracoronary or intravenous cangrelor bolus administration
(p = 0.762). No differences were found between the two treatment strategies regarding post 
procedural TIMI frame count (30.08 ± 18.1 vs. 26.8 ± 13.4; p = 0.258), even analyzing the 
sub-group with LAD as culprit vessel (25.1 ± 11.4 vs. 25.5 ± 14.9; p = 0.710). Also, no 
differences were found considering the median and the 75° percentile dichotomous cut-off 
values for the analyses (p = 0.390 and p = 0.525, respectively).
QTd analysis showed similar results between the two study cohorts early at 30 min 
after the primary PCI procedure (57.7 ± 26.5 ms vs. 57.1 ± 27.7 ms; p = 0.880) and at 24 
hours (53.1 ± 24.4 vs. 58.1 ± 21.9; p = 0.591).
No ischemic events or stent thrombosis occurred at 30 days. Two (5.4%) patients in the
intracoronary group and 1 (2.9%) patient in the intravenous group experienced cardiac death, 
due to refractory heart failure, before hospital discharge (p = 0.606). All bleedings and BARC 
≥ 3 bleeding events were not related to intracoronary or intravenous cangrelor bolus 
administration (Table 2); 11 BARC ≥ 3 bleeding events occurred in the study population 
(15%), and out of these, 7 (63%) were in the femoral procedures. No other clinical events 
occurred.
DISCUSSION
The main findings of the study can be summarized as follows: 1) intracoronary 
administration of cangrelor was not associated with an improved myocardial reperfusion; 
conversely, intravenous bolus administration was associated with a significantly improved 
reperfusion assessed by an early and late STR; 2) no acute or sub-acute stent thrombosis 
occurred, and 3) no differences in terms of clinically relevant/significant bleedings (BARC 
3–5) were found between groups. 
Intravenous cangrelor bolus administration was associated with a greater early STR ≥ 
50% and other surrogate indices of myocardial reperfusion. Intravenous bolus administration 
resulted independently associated with STR, even after the multivariable adjustment for the 
most important clinical variables. The association was significant for 30 min STR ≥ 50% and
30 min STR ≥ 70%, and for 24 hours STR ≥ 50%, which is known to be related to myocardial 
reperfusion and salvage [15–20].
The mechanisms involved and the explanation of this phenomenon are not completely 
clear. It could be hypothesized that the result could be favored by different timing of 
drug administration: the intracoronary administration by guiding catheter after the 
cannulation of the coronary “culprit” vessel could lead to a delay of action of the drug as 
compared to an earlier conventional intravenous bolus administration, which is performed 
immediately after the diagnostic coronary angiography. Thus, it can be  supposed that an 
earlier administration could overcome a higher local drug concentration. In particular, the 
mechanical instrumentation by primary PCI of the “culprit” vessel, immediately after the 
intracoronary bolus, would occur without an adequate platelet inhibition by cangrelor. This 
could favor distal embolization and micro-embolization phenomena; as known, micro-
embolization plays a crucial role in the intracoronary flow pathophysiology, leading to 
microvascular thrombosis, vasoconstriction and myocardial inflammation [21]. These 
pathophysiologic effects are associated with clinical outcome and prognosis. According to 
available literature, the absence of ST-segment resolution after the procedure is associated with
microcirculation dysfunction [22], leading to greater myocardial damage and increased 
cardiovascular mortality and reinfarction at 1 and 3 years [20, 23].
Therefore, the small sample size derived data herein, support how different routes of
cangrelor administration could affect myocardial reperfusion in primary PCI, and 
consequently the clinical outcome of patients.
As previously reported, in the present population study, non-LAD coronary artery 
“culprit” vessel was associated with a higher rate of STR [19, 24]. In the study by 
Schröder et al. [19], comparing different methods of ST-segment resolution, the anterior 
acute myocardial infarction was associated with less reduction in STR; furthermore, the 
group of patients considered to be at low risk for complete resolution of ST-segment 
elevation, included more than two-thirds of the total number of patients with inferior acute 
myocardial infarction [19]. The randomized JETSTENT multicenter trial, compared 
rheolytic thrombectomy before direct stenting to direct stenting alone in STEMI patients 
undergoing primary PCI. The study that assessed myocardial reperfusion by early STR, 
showed a significant inverse correlation of anterior acute myocardial infarction with early 
resolution of the ST-segment elevation by multivariable analysis [24].
Thrombectomy was more frequently used in the intravenous bolus cohort of the 
study. However, it was not related to STR in univariable and multivariable analyses. In 
accordance to the current guidelines [25], thrombectomy was employed in patients with a 
large or massive thrombus-containing lesion and/or in bailout situations. Furthermore, no 
interaction was found between thrombectomy and intracoronary or intravenous bolus of 
cangrelor administration.
Renal insufficiency (defined as eGFR < 60 mL/min) was associated with a worse 
myocardial reperfusion, as shown by univariable and multivariable analysis. R enal 
impairment does not affect pharmacocynetic and pharmacodynamic of cangrelor. Instead, it is 
possible that the known negative effect of the renal insufficiency on the endothelial function 
and its pro-thrombotic effects, other than the favorable calcium deposition in the coronary 
circle, could be associated with an impairment of myocardial reperfusion. In available 
literature, data show that renal insufficiency is a  predictor of worse post-procedural 
coronary flow (measured by the TIMI flow grade) after reperfusion [26, 27]; these data 
could correlate with a low rate of STR.
Finally, the small sample size of the pilot study prevents inferences about the 
exploratory clinical outcomes. Nevertheless, no concerning results emerged about the 
safety with the intracoronary bolus administration of cangrelor.
The present study must be evaluated in light of several limitations. Firstly, data derived 
from a single-center prospective registry. The study was mechanistic in nature and was not 
powered for clinical end points. Despite the use of multivariable analysis, it remains 
unknown if residual confounders may have affected the results in the present analyses. 
Another limitation was the number of patients that made type II errors possible. It must be 
acknowledged that this study did not show a cause-and-effect relationship, but only an 
association. Thus, the results of this study should be considered only as hypothesis generating.
CONCLUSIONS
In conclusion, the results of our study do not show any advantages from the administration 
of intracoronary bolus of cangrelor in patients affected by STEMI and treated with primary PCI.
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y (n = 
37)
Intraveno
us (n = 
34)
P
Age [years] 65.6 ±13.3 67.1 ± 13 64.12 ± 13.6 0.563
Female 15 (21.1%) 9 (24.3%) 6 (17.6%) 0.491
Familiar history of 
CAD
21 (29.6%) 11 (32.4%) 10 (27%) 0.623
Hypertension 40 (56.3%) 24 (64.9%) 16 (47.1%) 0.131
Dyslipidemia 30 (42.3%) 14 (37.8%) 16 (47.1%) 0.432
Diabetes 12 (16.9%) 6 (16.2%) 6 (17.6%) 0.862
Active smokers 39 (54.9%) 23 (62.2%) 16 (47.1%) 0.201
PAD 7 (9.9%) 4 (10.8%) 3 (8.8%) 0.779
Previous PCI 11 (15.5%) 5(13.5%) 6 (17.6%) 0.631
CKD 10 (14.1%) 6 (16.2%) 4 (11.76%) 0.590
Baseline ST-segment
elevation:
Mean ± SD [mm] 2.79 ± 1.83 2.80 ± 1.61 2.78 ± 2.07 0.273
Median [IQR] [mm] 2.5 [1.5–3.5] 2.75 [1.62–3.5] 2.25 [1.5–3.88] 0.720
CKD — chronic kidney disease; IQR — interquartile range; PAD — peripheral artery disease; PCI 
— percutaneous coronary intervention; SD — standard deviation





y (n = 37)
Intravenou






20 (54.1%) 20 (58.8%)
CX 5 
(7.0%)
2 (5.4%) 3 (8.8%)
RCA 26 
(36.6%)
14 (37.8%) 12 (35.3%)
TIMI 0–1 55 
(78%)
27 (74%) 28 (82%) 0.344
Multivessel CAD 44 
(62%)
24 (64%) 20 (59%) 0.274
Type B2 and C lesion
68 
(97%)




5 (13.4%) 16 (50%) 0.002
Manual 3 
(4.2%)
1 (2.9%) 2 (5.5%) 0.506
Stent recipients 71 
(100%)
37 (100%) 34 (100%)
Type of stents
Second generation EES (n) 103 45 58




1.24 ± 0.59 1.61 ± 0.69




30 (81.1%) 18 (52.9%) 0.11
Femoral 23 
(32.4%)
7 (18.9%) 16 (47.1%) 0.11
Procedural success 71 
(100%)




37 (100%) 34 (100%) 1.00
CAD — coronary artery disease; CX — circumflex, IQR — inter-quartile range; EES — everolimus eluting stent; 
LAD — left anterior descending; RCA — right coronary artery 
Figure 1. ST-segment elevation resolution as surrogate of myocardial reperfusion; IC — 
intracoronary, IV— intravenous.
Figure 2. Adjusted analysis of predictors associated with early ST-elevation resolution ≥ 50%; 
CI — confidence interval; CKD — chronic kidney disease; IV — intravenous; LAD — left 
anterior descending; OR — odds ratio; STR — ST-elevation reduction.


